Overview: AML ETO t(8;21) Quantitative TestIntroduction: The AML ETO t(8;21) Quantitative Test monitors minimal residual disease in leukemia by measuring the AML1-ETO gene rearrangement, aiding in tracking treatment response in acute myeloid leukemia (AML). Following 2023 NCCN guidelines, it uses PCR for high sensitivity, critical for guiding therapy adjustments and improving outcomes in molecular pathology for patients with AML.
Other Names: AML ETO Quantitative Assay, t(8;21) MRD Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: AML genetic testing advanced in the 1990s with PCR. Quantitative PCR for t(8;21) emerged in the 2000s, improving minimal residual disease detection.
Purpose: Monitors AML treatment response, guides therapy adjustments, and assesses relapse risk in patients with fatigue or frequent infections.
Test Parameters: 1. AML ETO t(8;21) Gene Rearrangement
Pretest Condition: No fasting required. Collect whole blood or bone marrow at any time. Report symptoms like fatigue or infections, and list chemotherapy or transplant history.
Specimen: 2-5 mL whole blood (EDTA) or 2-5 mL bone marrow (EDTA). Transport in a biohazard bag within 24 hours to maintain sample integrity.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document AML diagnosis, treatment history, or family history of leukemia. Include current medications, especially chemotherapy or immunosuppressive drugs.
Consent: Written consent required, detailing the tests purpose, diagnostic implications, and potential need for therapy adjustments.
Procedural Considerations: Uses quantitative PCR to measure AML ETO t(8;21) levels. Results are available in 3-5 days, supporting clinical decisions.
Factors Affecting Result Accuracy: Improper storage or delayed transport can degrade nucleic acids. Contamination or low sample quality may affect PCR sensitivity.
Clinical Significance: Detectable AML ETO levels indicate residual disease, prompting therapy intensification. Undetectable levels suggest remission, guiding maintenance therapy.
Specialist Consultation: Consult a hematologist or oncologist for result interpretation. A molecular pathologist referral is advised for complex cases.
Additional Supporting Tests: AML ETO qualitative test, flow cytometry, or cytogenetic analysis to confirm AML status or monitor disease.
Test Limitations: Low-level disease may be missed due to PCR sensitivity limits. Results require clinical correlation with other AML markers.
References: NCCN AML Guidelines, 2023; Blood, Dohner H, 2022.
